Filing Details

Accession Number:
0000899243-23-013992
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-26 20:00:11
Reporting Period:
2023-05-24
Accepted Time:
2023-05-26 20:00:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1770121 Sana Biotechnology Inc. SANA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222012 Noubar Afeyan 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
1627639 Flagship Ventures Fund V, L.p. 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
1724575 Flagship Ventures Fund V General Partner Llc 55 Cambridge Parkway
Suite 800E
Cambridge MA 02142
No No Yes No
1724939 Flagship V Venturelabs Rx Fund, L.p. 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-05-24 308,290 $6.57 11,276,909 No 4 S Indirect By Flagship Ventures Fund V, L.P.
Common Stock Disposition 2023-05-24 39,580 $6.57 1,447,791 No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
Common Stock Disposition 2023-05-25 102,245 $6.35 11,174,664 No 4 S Indirect By Flagship Ventures Fund V, L.P.
Common Stock Disposition 2023-05-25 13,127 $6.35 1,434,664 No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
Common Stock Disposition 2023-05-26 72,670 $6.23 11,101,994 No 4 S Indirect By Flagship Ventures Fund V, L.P.
Common Stock Disposition 2023-05-26 9,330 $6.23 1,425,334 No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Flagship Ventures Fund V, L.P.
No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
No 4 S Indirect By Flagship Ventures Fund V, L.P.
No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
No 4 S Indirect By Flagship Ventures Fund V, L.P.
No 4 S Indirect By Flagship V VentureLabs Rx Fund, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 11,441,326 Indirect By Flagship VentureLabs V, LLC
Common Stock 9,725,122 Indirect By Flagship Pioneering Fund VI, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
  3. Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
  7. Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.